Glioblastoma Multiforme
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
HPO |
|
|
|
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We have examined the relative roles of the two major phospholipid products of PI3K activity, phosphatidylinositol 3,4-biphosphate [PtdIns(3,4)P2] and phosphatidylinositol 3,4,5-triphosphate [PtdIns(3,4,5)P3], in the regulation of PKB activity in glioblastoma cells containing high levels of both of these lipids due to defective PTEN expression.
|
10958682 |
2000 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Downregulation of uPA inhibits migration and PI3k/Akt signaling in glioblastoma cells.
|
12545160 |
2003 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results suggest that genetic alterations of class IA PI3K subunit genes can occasionally play a role in human glioblastoma by activating the PI3K-AKT signaling pathway independently of PTEN mutation.
|
15605984 |
2004 |
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations in glioblastoma multiforme.
|
15924253 |
2005 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells.
|
16007122 |
2005 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Inhibition of PI3K in U87MG glioblastoma cells, which have activated PI3K/Akt activity secondary to phosphatase and tensin homologue deleted on chromosome 10 (PTEN) mutation, with LY294002 blunted the induction of HIF-1alpha protein and its targets vascular endothelial growth factor and glut1 mRNA in response to hypoxia.
|
16849522 |
2006 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our findings highlight the important influence in GBM of signaling pathways such as the PI3K/AKT, consistent with the invasive features of this tumor.
|
17002787 |
2006 |
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Given this disparity and to address the relation of patient age to mutation frequency, we examined 10 exons of PIK3CA in 73 glioblastoma samples by PCR amplification followed by direct DNA sequencing.
|
17050665 |
2006 |
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Introduction of normal PTEN together with H-Ras(G12V) into U251 glioblastoma cells reduced the PI3K-dependent activation of Akt, but had no effect on vacuolation.
|
17210246 |
2007 |
Glioblastoma Multiforme
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Only one glioblastoma showed both PIK3CA mutation and amplification.
|
17235514 |
2007 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis.
|
17616812 |
2007 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Rapamycin has anticancer activity in PTEN-deficient glioblastoma and warrants further clinical study alone or in combination with PI3K pathway inhibitors.
|
18215105 |
2008 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In addition, activation of the PI3K/Akt pathway was demonstrated in this set of GBMs.
|
18260157 |
2008 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results uncover CD95 as an activator of PI3K and, most importantly, as a crucial trigger of basal invasion of glioblastoma in vivo.
|
18328427 |
2008 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
For example, combining gefitinib with inhibitors of the PI3K/AKT pathway show enhanced cytotoxicity in glioblastoma derived cell lines.
|
18566746 |
2008 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
The suggested dependence of glioblastoma tumors on PI3K signaling implies that PI3K inhibitors should lead to effective killing of these cancer cells, but that has been shown not to be the case.
|
19076776 |
2009 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data indicate that in GBM oncogenic deregulation of the PI3K pathway does not involve somatic mutations in the coding region of AKT1.
|
19461960 |
2009 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is altered in most glioblastoma multiforme.
|
19549905 |
2009 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
By identifying class I PI3K inhibitors as powerful agents in enhancing the lethality of DNA-damaging drugs, to which GBMs are usually considered unresponsive, our findings have important implications for the design of rational combination regimens in overcoming the frequent chemoresistance of GBM.
|
19633683 |
2009 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, HOXA9 activation is a novel, independent, and negative prognostic marker in GBM that is reversible through a PI3K-associated epigenetic mechanism.
|
20068170 |
2010 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
We confirm and extend the observation that GBM alterations tend to occur within specific functional modules, in spite of considerable patient-to-patient variation, and that two of the largest modules involve signaling via p53, Rb, PI3K and receptor protein kinases.
|
20169195 |
2010 |
Glioblastoma Multiforme
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, we demonstrate that the extracellular signal-regulated kinase (ERK)1/2 pathway is only partially implicated in the modulation of CXCL12-induced glioblastoma cell movement, whereas the phosphoinositol-3 kinase (PI3K) pathway is not involved.
|
20392929 |
2010 |
Glioblastoma Multiforme
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The PI3K pathway is commonly activated in glioblastoma and promotes tumor cell survival, suggesting that its inhibition would make cells more sensitive to cytotoxic agents.
|
20473884 |
2011 |